Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma

Multiple Myeloma Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01450215
• Other study ID #: PI-RV-MM-10-07/ RV-MM-PI 0627
• Secondary ID: 2010-021857-38
• Status: Completed
• Phase: Phase 2
• First received: September 7, 2011
• Last updated: March 24, 2016
• Start date: March 2011

Study information

• Verified date: March 2016
• Source: Karolinska University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Regional Ethical Review Board
• Study type: Interventional

Clinical Trial Summary

This is:

• A prospective, randomized, open, phase II, multi-centre, interventional study. Patients who are in at least PR and have received lenalidomide as 2nd line treatment for MM will be recruited.

• The patients will be randomized into two groups. Group R will receive lenalidomide 25 mg/day p.o. continuously for 21 days and group Rb will receive a similar dose of lenalidomide with the addition of 40 mg of dexamethasone p.o. on days 1, 8, 15 and 22 of every 28 day treatment cycle. Study includes a maximum of 24 cycles including two consolidating cycles per patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Inclusion Criteria - all subjects must:

1. Be at least 18 years of age

2. Subjects must have a documented diagnosis of MM and have either refractory or relapsed and refractory after first line treatment disease defined as:

• Primary refractory

• Refractory

• Relapsed and Refractory

3. Subjects must have undergone prior treatment with one treatment line of anti-myeloma therapy. Induction therapy followed by ASCT and consolidation/maintenance will be considered as one line.Have a confirmed diagnosis of MM

4. Have received lenalidomide after one prior treatment for MM and have reached at least a partial response (PR), according to IMWG criteria, including two consolidating cycles. Subjects have experienced a response at least PR after starting treatment with lenalidomide and cortisone cycles.

5. Have personally signed and dated a legally effective written informed consent form prior to admission to the study.

6. Must be willing and able to understand and comply with the study requirements.

7. Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception.

8. Male must agree to practice contraception

Exclusion Criteria:

1. Any of the following laboratory abnormalities:

• Absolute neutrophil count (ANC) < 1,000/µL

• Platelet count < 75,000/ µL

• Creatinine Clearance < 45 mL/min according to Cockcroft-Gault formula

• Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)

• Serum total bilirubin > 2.0 mg/dL

2. ECOG performance status <4.

3. Individuals who have had a stem-cell transplant as a 2nd line treatment for MM

4. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening.

5. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.

6. Pregnant or lactating females.

7. Any other clinically significant medical disease or condition that, in the Investigator´s opinion, may interfere with protocol adherence or a subject´s ability to give informed consent.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Revlimid
Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .

Locations

Country	Name	City	State
Sweden	Karolinska Inst.	Stockholm
Sweden	Karolinska Institute	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Karolinska University Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to progression		24 months	No
Secondary	Number of Participants with Adverse Events	Number of Participants with Adverse Events	participants will be followed for the duration of hospital stay, an expected average of 2 years	Yes